Compare Asana Inc. (ASAN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Asana Inc. vs 10X Genomics Inc — how do they compare? Asana Inc. trades at $7.36 (market cap $1.69B), while 10X Genomics Inc trades at $42.26 (market cap $5.43B). The key difference: 10X Genomics Inc is far larger — about 3.2× Asana Inc.'s market cap, and 10X Genomics Inc is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ASAN | TXG | |
|---|---|---|
Market Cap | $1.69B | $5.43B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.35 | $43.10 |
52-Week Low | $5.46 | $11.34 |
Enterprise Value | $1.51B | $4.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $7.33, down 0.54% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $378M in 2022 to $724M in 2025, though net losses persist. Recent Q1 2027 earnings beat expectations at $0.10 per share, and strategic acquisitions like StackAI enhance AI capabilities. Analyst consensus is mixed with 42% buy ratings and a $9.86 price target, representing 35% upside from current levels.
The outlook balances growth potential against profitability challenges. Positive catalysts include FedRAMP authorization for government contracts and AI innovation, but risks stem from intense competition with Microsoft and decelerating revenue growth. Cash flow turned positive in 2025, yet negative margins and high valuation multiples require careful monitoring for sustained improvement.
TXG trades at $42.73, down 0.86% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth and beat EPS estimates, with net losses narrowing significantly from -$166M in 2022 to -$44M in 2025. Recent collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics highlight strategic expansion in diagnostics and multiomics capabilities.
Outlook remains cautiously optimistic as improving margins and cash flow support growth, but high valuation multiples and persistent net losses pose risks. Analyst consensus is mixed with a $35.14 price target below current levels, suggesting limited near-term upside despite positive operational trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
